Literature DB >> 21646302

Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels.

Suzette J Bielinski1, High Seng Chai, Jyotishman Pathak, Jayant A Talwalkar, Paul J Limburg, Rachel E Gullerud, Hugues Sicotte, Eric W Klee, Jason L Ross, Jean-Pierre A Kocher, Iftikhar J Kullo, John A Heit, Gloria M Petersen, Mariza de Andrade, Christopher G Chute.   

Abstract

OBJECTIVE: To create a cohort for cost-effective genetic research, the Mayo Genome Consortia (MayoGC) has been assembled with participants from research studies across Mayo Clinic with high-throughput genetic data and electronic medical record (EMR) data for phenotype extraction. PARTICIPANTS AND METHODS: Eligible participants include those who gave general research consent in the contributing studies to share high-throughput genotyping data with other investigators. Herein, we describe the design of the MayoGC, including the current participating cohorts, expansion efforts, data processing, and study management and organization. A genome-wide association study to identify genetic variants associated with total bilirubin levels was conducted to test the genetic research capability of the MayoGC.
RESULTS: Genome-wide significant results were observed on 2q37 (top single nucleotide polymorphism, rs4148325; P=5.0 × 10(-62)) and 12p12 (top single nucleotide polymorphism, rs4363657; P=5.1 × 10(-8)) corresponding to a gene cluster of uridine 5'-diphospho-glucuronosyltransferases (the UGT1A cluster) and solute carrier organic anion transporter family, member 1B1 (SLCO1B1), respectively.
CONCLUSION: Genome-wide association studies have identified genetic variants associated with numerous phenotypes but have been historically limited by inadequate sample size due to costly genotyping and phenotyping. Large consortia with harmonized genotype data have been assembled to attain sufficient statistical power, but phenotyping remains a rate-limiting factor in gene discovery research efforts. The EMR consists of an abundance of phenotype data that can be extracted in a relatively quick and systematic manner. The MayoGC provides a model of a unique collaborative effort in the environment of a common EMR for the investigation of genetic determinants of diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21646302      PMCID: PMC3127556          DOI: 10.4065/mcp.2011.0178

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  20 in total

Review 1.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Authors:  R H Tukey; C P Strassburg
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects.

Authors:  Ichiro Ieiri; Hiroshi Suzuki; Miyuki Kimura; Hiroshi Takane; Yohei Nishizato; Shin Irie; Akinori Urae; Kiyoshi Kawabata; Shun Higuchi; Kenji Otsubo; Yuichi Sugiyama
Journal:  Hepatol Res       Date:  2004-10       Impact factor: 4.288

3.  Genome-wide association meta-analysis for total serum bilirubin levels.

Authors:  Andrew D Johnson; Maryam Kavousi; Albert V Smith; Ming-Huei Chen; Abbas Dehghan; Thor Aspelund; Jing-Ping Lin; Cornelia M van Duijn; Tamara B Harris; L Adrienne Cupples; Andre G Uitterlinden; Lenore Launer; Albert Hofman; Fernando Rivadeneira; Bruno Stricker; Qiong Yang; Christopher J O'Donnell; Vilmundur Gudnason; Jacqueline C Witteman
Journal:  Hum Mol Genet       Date:  2009-05-04       Impact factor: 6.150

4.  Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease.

Authors:  Arno Lingenhel; Barbara Kollerits; Johannes P Schwaiger; Steven C Hunt; Richard Gress; Paul N Hopkins; Veit Schoenborn; Iris M Heid; Florian Kronenberg
Journal:  Exp Gerontol       Date:  2008-08-26       Impact factor: 4.032

5.  Role of cysteine residues in the function of human UDP glucuronosyltransferase isoform 1A1 (UGT1A1).

Authors:  Siddhartha S Ghosh; Yang Lu; Sung W Lee; Xia Wang; Chandan Guha; Jayanta Roy-Chowdhury; Namita Roy-Chowdhury
Journal:  Biochem J       Date:  2005-12-15       Impact factor: 3.857

6.  Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study.

Authors:  L Bathum; H C Petersen; J U Rosholm; P Hyltoft Petersen; J Vaupel; K Christensen
Journal:  Clin Chem       Date:  2001-01       Impact factor: 8.327

7.  Genetic influences on serum bilirubin in American Indians: The Strong Heart Family Study.

Authors:  Phillip E Melton; Karin Haack; Harald H Göring; Sandy Laston; Jason G Umans; Elisa T Lee; Richard R Fabsitz; Richard B Devereux; Lyle G Best; Jean W Maccluer; Laura Almasy; Shelley A Cole
Journal:  Am J Hum Biol       Date:  2011 Jan-Feb       Impact factor: 1.937

8.  Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population.

Authors:  Rong Lin; Ying Wang; Yi Wang; Wenqing Fu; Dandan Zhang; Hongxiang Zheng; Ting Yu; Ying Wang; Min Shen; Rong Lei; Hong Wu; Aijun Sun; Ruifang Zhang; Xiaofeng Wang; Momiao Xiong; Wei Huang; Li Jin
Journal:  Pharmacogenet Genomics       Date:  2009-04       Impact factor: 2.089

9.  OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.

Authors:  Wei Zhang; Yi-Jing He; Zhou Gan; Lan Fan; Qing Li; An Wang; Zhao-Qian Liu; Sheng Deng; Yuan-Fei Huang; Lin-Yong Xu; Hong-Hao Zhou
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-12       Impact factor: 2.557

10.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.

Authors:  Gloria M Petersen; Laufey Amundadottir; Charles S Fuchs; Peter Kraft; Rachael Z Stolzenberg-Solomon; Kevin B Jacobs; Alan A Arslan; H Bas Bueno-de-Mesquita; Steven Gallinger; Myron Gross; Kathy Helzlsouer; Elizabeth A Holly; Eric J Jacobs; Alison P Klein; Andrea LaCroix; Donghui Li; Margaret T Mandelson; Sara H Olson; Harvey A Risch; Wei Zheng; Demetrius Albanes; William R Bamlet; Christine D Berg; Marie-Christine Boutron-Ruault; Julie E Buring; Paige M Bracci; Federico Canzian; Sandra Clipp; Michelle Cotterchio; Mariza de Andrade; Eric J Duell; J Michael Gaziano; Edward L Giovannucci; Michael Goggins; Göran Hallmans; Susan E Hankinson; Manal Hassan; Barbara Howard; David J Hunter; Amy Hutchinson; Mazda Jenab; Rudolf Kaaks; Charles Kooperberg; Vittorio Krogh; Robert C Kurtz; Shannon M Lynch; Robert R McWilliams; Julie B Mendelsohn; Dominique S Michaud; Hemang Parikh; Alpa V Patel; Petra H M Peeters; Aleksandar Rajkovic; Elio Riboli; Laudina Rodriguez; Daniela Seminara; Xiao-Ou Shu; Gilles Thomas; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Stephen K Van Den Eeden; Jarmo Virtamo; Jean Wactawski-Wende; Zhaoming Wang; Brian M Wolpin; Herbert Yu; Kai Yu; Anne Zeleniuch-Jacquotte; Joseph F Fraumeni; Robert N Hoover; Patricia Hartge; Stephen J Chanock
Journal:  Nat Genet       Date:  2010-01-24       Impact factor: 38.330

View more
  36 in total

Review 1.  The role of phenotype in gene discovery in the whole genome sequencing era.

Authors:  Laura Almasy
Journal:  Hum Genet       Date:  2012-06-22       Impact factor: 4.132

2.  CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation.

Authors:  Cody C Wyles; Christopher R Paradise; Matthew T Houdek; Susan L Slager; Andre Terzic; Atta Behfar; Andre J van Wijnen; Rafael J Sierra
Journal:  Clin Orthop Relat Res       Date:  2019-08       Impact factor: 4.176

3.  Electronic health records-driven phenotyping: challenges, recent advances, and perspectives.

Authors:  Jyotishman Pathak; Abel N Kho; Joshua C Denny
Journal:  J Am Med Inform Assoc       Date:  2013-12       Impact factor: 4.497

4.  Genome-wide association studies go green: novel and cost-effective opportunities for identifying genetic associations.

Authors:  Celine M Vachon
Journal:  Mayo Clin Proc       Date:  2011-07       Impact factor: 7.616

5.  Mining the human phenome using semantic web technologies: a case study for Type 2 Diabetes.

Authors:  Jyotishman Pathak; Richard C Kiefer; Suzette J Bielinski; Christopher G Chute
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

6.  Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics.

Authors:  Matthew K Breitenstein; Gyorgy Simon; Euijung Ryu; Sebastian M Armasu; Richard M Weinshilboum; Liewei Wang; Jyotishman Pathak
Journal:  Stud Health Technol Inform       Date:  2015

Review 7.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Authors:  Robert J Fontana
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

Review 8.  SLC transporters as therapeutic targets: emerging opportunities.

Authors:  Lawrence Lin; Sook Wah Yee; Richard B Kim; Kathleen M Giacomini
Journal:  Nat Rev Drug Discov       Date:  2015-06-26       Impact factor: 84.694

Review 9.  The intelligent use and clinical benefits of electronic medical records in multiple sclerosis.

Authors:  Mary F Davis; Jonathan L Haines
Journal:  Expert Rev Clin Immunol       Date:  2014-12-11       Impact factor: 4.473

Review 10.  The SLCO (former SLC21) superfamily of transporters.

Authors:  Bruno Hagenbuch; Bruno Stieger
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.